scholarly journals Developmental and reproductive safety evaluation of AV7909 anthrax vaccine candidate in rats

2020 ◽  
Vol 113 (1) ◽  
pp. 32-42
Author(s):  
Eve Mylchreest ◽  
M. Autumn Smiley ◽  
Jeff D. Ballin ◽  
Bruna Blauth ◽  
Jeffry Shearer ◽  
...  
Keyword(s):  
Vaccine Candidate ◽  
Safety Evaluation ◽  
Anthrax Vaccine

Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis

2009 ◽  
Vol 81 (10) ◽  
pp. 1777-1785 ◽  
Author(s):  
Natalia S. Pripuzova ◽  
Natalia V. Tereshkina ◽  
Larissa V. Gmyl ◽  
Tatiana I. Dzhivanyan ◽  
Alexander A. Rumyantsev ◽  
...  
Keyword(s):  
Vaccine Candidate ◽  
Safety Evaluation ◽  
Live Vaccine ◽  
Tick Borne Encephalitis

Stability and pre-formulation development of a plant-produced anthrax vaccine candidate

Vaccine ◽  
2017 ◽  
Vol 35 (41) ◽  
pp. 5463-5470 ◽  
Author(s):  
R. Mark Jones ◽  
Michael Burke ◽  
Devon Dubose ◽  
Jessica A. Chichester ◽  
Slobodanka Manceva ◽  
...  
Keyword(s):  
Vaccine Candidate ◽  
Formulation Development ◽  
Anthrax Vaccine

Repeat Dose Toxicity Study of the AV7909 Anthrax Vaccine Candidate in Juvenile Rats

2020 ◽  
Vol 39 (5) ◽  
pp. 443-451
Author(s):  
Amy Zmarowski ◽  
Jeff D. Ballin ◽  
Jessica Sharits ◽  
Kevin Carrico ◽  
Joseph Novak ◽  
...  
Keyword(s):  
Vaccine Candidate ◽  
Clinical Chemistry ◽  
Pediatric Population ◽  
Recovery Period ◽  
Post Exposure Prophylaxis ◽  
Repeat Dose ◽  
Local Tolerance ◽  
Juvenile Rats ◽  
Anthrax Vaccine ◽  
Biomarker Analysis

AV7909 is a next-generation anthrax vaccine candidate indicated for post-exposure prophylaxis of exposure to Bacillus anthracis. AV7909 consists of the Anthrax Vaccine Adsorbed (AVA) bulk drug substance and the immunostimulatory Toll-like receptor 9 agonist oligodeoxynucleotide adjuvant, CPG 7909. Safety testing for pediatric population is warranted to support the potential emergency use of AV7909 in children. This study was conducted to investigate the local tolerance and potential systemic toxicity and their reversibility in juvenile rats by repeat intramuscular injections of the AV7909 vaccine candidate. Animals were dosed on postnatal day (PND) 21 (at weaning), PND 28, and PND 35, with the test article (AV7909), the adjuvant alone (Alhydrogel + CPG 7909), or sterile water for injection. Core group animals were necropsied on PND 37 and recovery group on PND 49. Study end points included survival, clinical observations, injection site observations, body weights, clinical pathology (hematology, coagulation, and clinical chemistry), pro-inflammatory biomarker analysis (alpha-2 macroglobulin [A2M] and alpha-1 acid glycoprotein [AGP]), and anatomic pathology. Immune response to vaccination was measured using the high-throughput anthrax lethal toxin neutralization assay (htpTNA). The AV7909 vaccine candidate produced no apparent systemic or local toxicity. The AGP and A2M levels were elevated in both the adjuvant-alone and AV7909 groups at the end of treatment but were comparable to control levels by the end of the recovery period. All animals in the AV7909 group demonstrated a robust neutralizing antibody response. The results indicate that AV7909 has a favorable safety profile in juvenile rats.

scholarly journals Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart

Vaccine ◽  
2021 ◽  
Vol 39 (1) ◽  
pp. 1-5
Author(s):  
Jeffry D. Shearer ◽  
Lisa Henning ◽  
Daniel C. Sanford ◽  
Na Li ◽  
Mario H. Skiadopoulos ◽  
...  
Keyword(s):  
Guinea Pigs ◽  
Nonhuman Primates ◽  
Vaccine Candidate ◽  
Anthrax Vaccine

scholarly journals Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate

Vaccine ◽  
2017 ◽  
Vol 35 (37) ◽  
pp. 4952-4959 ◽  
Author(s):  
Vladimir Savransky ◽  
Jeffry D. Shearer ◽  
Melicia R. Gainey ◽  
Daniel C. Sanford ◽  
Gloria S. Sivko ◽  
...  
Keyword(s):  
Guinea Pigs ◽  
Nonhuman Primates ◽  
Vaccine Candidate ◽  
Neutralizing Antibody ◽  
Lethal Toxin ◽  
Anthrax Lethal Toxin ◽  
Anthrax Vaccine ◽  
Antibody Levels

scholarly journals Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909

Vaccine ◽  
2019 ◽  
Vol 37 (43) ◽  
pp. 6356-6361 ◽  
Author(s):  
M. Autumn Smiley ◽  
Daniel C. Sanford ◽  
Cheryl A. Triplett ◽  
Daniel Callahan ◽  
Vladimir Frolov ◽  
...  
Keyword(s):  
Vaccine Candidate ◽  
Liquid Formulation ◽  
Anthrax Vaccine

scholarly journals A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potential anthrax vaccine candidate

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jun Ho Jeon ◽  
Yeon Hee Kim ◽  
Kyung Ae Kim ◽  
Yu-Ri Kim ◽  
Sun-Je Woo ◽  
...  
Keyword(s):  
Protective Antigen ◽  
Vaccine Candidate ◽  
Protective Efficacy ◽  
Nuclear Factor Κb ◽  
Enzyme Linked Immunosorbent Assay ◽  
Potent Inducer ◽  
Anthrax Vaccine ◽  
Monocyte Chemoattractant Protein 1 ◽  
Mitogen Activated Protein ◽  
Gp Model

Abstract Background Bacillus ancthracis causes cutaneous, pulmonary, or gastrointestinal forms of anthrax. B. anthracis is a pathogenic bacterium that is potentially to be used in bioterrorism because it can be produced in the form of spores. Currently, protective antigen (PA)-based vaccines are being used for the prevention of anthrax, but it is necessary to develop more safe and effective vaccines due to their prolonged immunization schedules and adverse reactions. Methods We selected the lipoprotein GBAA0190, a potent inducer of host immune response, present in anthrax spores as a novel potential vaccine candidate. Then, we evaluated its immune-stimulating activity in the bone marrow-derived macrophages (BMDMs) using enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. Protective efficacy of GBAA0190 was evaluated in the guinea pig (GP) model. Results The recombinant GBAA0190 (r0190) protein induced the expression of various inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory protein-1α (MIP-1α) in the BMDMs. These immune responses were mediated through toll-like receptor 1/2 via activation of mitogen-activated protein (MAP) kinase and Nuclear factor-κB (NF-κB) pathways. We demonstrated that not only immunization of r0190 alone, but also combined immunization with r0190 and recombinant PA showed significant protective efficacy against B. anthracis spore challenges in the GP model. Conclusions Our results suggest that r0190 may be a potential target for anthrax vaccine.

Sign in / Sign up

Export Citation Format

Share Document